NEW Guidepoint Qsight Alpha Model: LivaNova

separator

by Robert Conklin, Vice President of Sales, Guidepoint Qsight With the addition of LivaNova (“LIVN”) to our Qsight Alpha product, we now have 17 company models available across the MedTech space. This timely data, gathered from over 2,000 healthcare facilities, offers clients new quantitative insights into LivaNova’s sales performance.   For LIVN, Qsight Alpha projections […]

Read More

Guidepoint Qsight Models: Medtronic Update

separator

by Robert Conklin, Vice President of Sales, Guidepoint Data With the addition of Medtronic (“MDT”) to our Guidepoint Qsight data-sets, we now have 16 company models available across the MedTech space. This timely data, gathered from over 2,000 medical facilities, offers clients new quantitative insights into Medtronic’s sales performance. We have updated our MDT projection […]

Read More

(NEW) Guidepoint Qsight Model: Medtronic

separator

by Robert Conklin, Vice President of Sales, Guidepoint Data With the addition of Medtronic (“MDT”) to our Guidepoint Qsight data-sets, we now have 16 company models available across the MedTech space. This timely data, gathered from over 1,500 hospitals, offers clients new quantitative insights into Medtronic’s sales performance.   For MDT, Qsight projections have been […]

Read More

(NEW) Guidepoint Qsight Models: SYK & BSX

separator

by Kenny Dolgin, Healthcare Analyst, Data Insights, Guidepoint Guidepoint’s Data Insights team is excited to announce that we have expanded Guidepoint Qsight’s data product offering to include models for Stryker (“SYK”) and Boston Scientific (“BSX”).   Prior to Stryker’s Q3 2018 earnings release, Qsight’s data and projection methodology showed potential for their U.S. revenue to […]

Read More

The Right Direction for your Research Needs

separator

When the right response from a research participant can make the difference for your end client, the ability to gather accurate insights from trusted respondents is critical for any companies’ decision-making process. Here’s how Guidepoint helps our clients ascertain the right information every time:     Through the unmatched speed of our offerings, we help […]

Read More

Guidepoint Helps Consultants Best Serve Their Clients

separator

One of the biggest challenges in an information-based economy is finding the right information when you need it. Whether it’s getting up to speed quickly on a project, or gaining insight on competitive landscapes, here’s how we help consulting firms serve their clients more efficiently.     Through our unmatched offerings, we give consultants the […]

Read More

Wright Medical: The Beginning of a Turnaround?

separator

by Kenny Dolgin, Healthcare Analyst, Data Insights, Guidepoint Wright Medical Group N.V. (NASDAQ: WMGI) is a mid-cap medical device company that competes in the orthopedics market with a focus on the upper extremities, lower extremities and biologics product areas. Key products include their INFINITY total ankle system, SIMPLICITI shoulder system, and AUGMENT bone graft. According […]

Read More

Will the Sinuva launch propel XENT to a higher level of growth?

separator

by Kenny Dolgin, Healthcare Analyst, Data Insights, Guidepoint Intersect ENT Inc. (NASDAQ: XENT) is a small-cap medical device company which competes in the ear, nose and throat (ENT) market. Since January 2017, Intersect’s stock price has grown 181% making it one of the top performing stocks in the medical device space over that period.   […]

Read More

Nevro – Spinal Cord Stimulation Market at a Crossroads

separator

by Ken Wahl, VP Business Development, Data Insights, Guidepoint Nevro Corp. (NYSE: NVRO) is a key player in the spinal cord stimulation (SCS) market. Since FDA approval of the Senza system in 2015, Nevro has taken ~15% market share from well-established market leaders Abbott/St. Jude, Medtronic and Boston Scientific. The U.S. SCS market was an […]

Read More

Can Abiomed sustain its impressive sales growth in FY 2019?

separator

by Kenny Dolgin, Data Insights, Guidepoint Abiomed, Inc. (NYSE: ABMD) is a leader in the percutaneous heart pump device market, having launched its first Impella device in 2008 and have since released four iterations with varying flow rates. From May 2013 to May 2018, Abiomed’s stock price delivered a 5-year CAGR of 75%, making it […]

Read More